The first trial compares the use of the patient's own stimulated killer cells (a part of one's natural immune system) to the use of chemotherapy in advanced lung cancer. The study is being carried out in China, so it is likely inaccessible to most US cancer patients, but it is a good example of how immunotherapy continues to be a major direction for cancer clinical trials.
The second trial tests a vaccine product called NeuVax (TM) to determine if the vaccine can prevent the relapse of breast cancer. Patients who have early stage node positive breast cancer that has low or intermediate expression of the HER2 protein are eligible. Experimental treatment follows the completion of standard treatments such as surgery, radiation, and chemotherapy.
You can click on the hyperlinks above to see each individual trial or click here to learn more about both of them:
New immunotherapy trials Dec 2011 (click here - link expires March 21, 2012)To see all 22 new phase III trials registered in the last 30 days, click here:
All new phase III cancer trials Dec 2011 (click here - link expires March 21, 2012)
